Drug misuse: findings from the 2016 to 2017 CSEW

| June 27, 2017

article image
The majority of ecstasy and powder cocaine users only take the drug once or twice a year 4.2% of 16-24s are frequent* drug users 2.0% of 16-59s are frequent* drug users Among 16-24s.in the last year 1.2% took new psychoactive substances 37% of cannabis users aged 16-59 are frequent* users 0.4% took new psychoactive substances (NPS) 1 in 5 used an illicit drug The type of NPS most recently used was most likely to be a herbal smoking mixture (40%) NPS use among 16 to 59 year olds has significantly decreased in the last year, from 0.7% to 0.4%.

Spotlight

Emitac Healthcare Solutions

With more than 40 years of experience in the industry, our integrated team of professionals have deployed several Clinical and IT Solutions in a number of leading government, semi government, Military and private hospitals in the MENA region. With our extensive market knowledge and well established partnerships with some of the world’s leading healthcare and technology providers, we continue delivering the highest standards of quality care. Through our unique combination of workforce empowerment, process improvement and technology optimization, we offer reliable and cost effective solutions to our customers to achieve sustainable results.

OTHER ARTICLES

Coronavirus Pandemic Brings Hundreds Of U.S. Clinical Trials To A Halt

Article | April 11, 2020

Rene Roach fired off a quick email in late March for an update on a colorectal cancer clinical trial for which she hoped to qualify. Worried about the coronavirus, she asked, almost as an afterthought, whether the study had been put on hold because of the pandemic.The answer crushed her: It had been. "That's when COVID-19 shut down everything," says Roach, 50, of Germantown, Md. Roach assumed that there would be workarounds for patients like her, who have stage IV cancer. These patients often depend on clinical trials as their best chance to knock cancer out when other therapies have failed. For now, she's being treated with traditional chemotherapy, but she was counting on the drug cocktail from the clinical trial. She figures if chemo was going to rid her body of cancer for good, it would have done so already.

Read More

Top Pharmaceutical Firms Urge FDA to Adopt Blockchain for Drug Tracking

Article | February 25, 2020

Leading market participants in the United States pharmaceutical industry, logistics firms, distributors and other stakeholders in the pharma supply chain have come together to publish a report buttressing the need for industry players to adopt blockchain for tracking prescription drugs, following the successful completion of a DLT pilot project with the Food and Drug Administration (FDA), according to reports on February 24, 2020. Though nascent, blockchain technology, the building blocks of Bitcoin (BTC) and other cryptocurrencies are fast gaining ground across various ecosystems, due to its immutability, security, privacy, and other intricate properties. In the latest development, 25 leading manufacturers of pharmaceutical products, logistics partners and other market participants in the pharma supply chain, have published a report that highlights the importance of blockchain technology in drug traceability.

Read More

What do you have to lose taking hydroxychloroquine for coronavirus? Potentially your life

Article | April 10, 2020

The president and some of his close advisors — desperate for a COVID-19 cure — are asking “What do you have to lose?” by taking hydroxychloroquine (HCQ), a strong medication never adequately tested for efficacy or safety in COVID-19 patients. The correct answer to the president’s question, which he doesn’t seem to want to hear, is that we have our lives to lose. The president acknowledges “I’m not a doctor” but this raises the question “What do doctors know about the drug recommended by the president? Most doctors are aware that HCQ can be effective for patients with malaria, arthritis or lupus. If they were to follow the president’s suggestion and prescribe it for COVID-19 patients, they would also like to know that it will benefit some of those patients, at least.

Read More

How Can Medical Cannabis Help to Manage Pain Conditions? – The Cannabis Exchange

Article | February 11, 2020

Pain management is one of the most common reasons for the use of medical cannabis products. However, despite many jurisdictions – including Canada, Germany, and the Netherlands – now allowing the prescription of medical cannabis for this purpose, there remains little ‘high-quality’ evidence to support, or oppose its efficacy. Madden et al. (2018) set out to review the evidence available in order to determine the efficacy of medical cannabis when employed in the management of various forms of musculoskeletal pain. The researchers analysed various studies that assessed the use of cannabinoids in the treatment of arthritis pain; back pain; postoperative pain; and trauma-related pain. It is estimated that up to 30% of the population may suffer from a non-cancer-related pain condition. As such a high percentage of people suffer from these conditions, the development of simple and safe therapies is an essential area of research. This is particularly important as the therapeutic options for people with chronic pain are increasingly limited.

Read More

Spotlight

Emitac Healthcare Solutions

With more than 40 years of experience in the industry, our integrated team of professionals have deployed several Clinical and IT Solutions in a number of leading government, semi government, Military and private hospitals in the MENA region. With our extensive market knowledge and well established partnerships with some of the world’s leading healthcare and technology providers, we continue delivering the highest standards of quality care. Through our unique combination of workforce empowerment, process improvement and technology optimization, we offer reliable and cost effective solutions to our customers to achieve sustainable results.

Events